

17 May 2011

## **Phosphagenics Bodyshaper Update**

Please find attached an announcement made to the ASX today by Phosphagenics Limited in respect to its Bodyshaper Cellulite Contour Cream which incorporates Calzada Ltd's AOD9604 technology.

### **For further information please contact:**

Dr Stewart Washer  
Chief Executive Officer  
Calzada Limited  
Mobile: 0418 288 212  
Email: [swasher@calzada.com.au](mailto:swasher@calzada.com.au)

### **About Calzada Ltd**

Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The company is listed on the Australian Securities Exchange (ASX Code CZD).

### **About PolyNovo Biomaterials Pty Ltd**

PolyNovo owns and develops a suite of highly prospective biodegradable polymers that have potential applications across numerous medical fields. The group has licence agreements and alliances with a number of the world's leading medical device companies and also has joint venture arrangements with local experts in the areas of skin repair.

### **About Metabolic Pharmaceuticals Pty Ltd**

Metabolic's major asset is the AOD9604 drug which has potential applications in the treatment of obesity and osteoporosis. AOD9604 is a small 16 amino acid peptide modeled on one segment of the human growth hormone molecule. Growth hormone occurs naturally in the body and has profound stimulatory effects on fat metabolism. Levels of the hormone are typically suppressed in the obese state and with increasing age. Counteraction of this imbalance by daily dosing with AOD9604 is believed to normalize suppressed fat metabolism in obese individuals, while avoiding unwanted effects of the whole growth hormone molecule.



PHOSPHAGENICS

*Company Announcement*

## **Phosphagenics to Launch BodyShaper Cellulite Contour Crème™**

- *ELIXIA® product range to be launched in selected Myer stores on Thursday, 20 May 2011*
- *BodyShaper reduces the appearance of cellulite by up to 56%*

**17 May 2011, Melbourne, Australia:** Melbourne biotechnology company Phosphagenics Limited (ASX: POH) will launch its novel anti-cellulite product in Australia's largest department store, Myer, on 20 May 2011.

The product, BodyShaper Cellulite Contour Crème™, uses the company's proprietary platform technology, TPM®, to deliver fat reducing molecules into the skin. The product includes the proprietary anti-fat peptide AOP9604 (which has been licensed to Phosphagenics) and two other lipolytic molecules, caffeine and forskolin.

The product release follows the completion of international trials during which women used the product for eight weeks. The results showed a marked reduction in the appearance of the cellulite at the application sites (up to 40% after 4 weeks and up to 56% after 8 weeks). Importantly, there was also improvement in skin elasticity and hydration and, of the women involved, 90% reported a perceived improvement in the visible appearance of their cellulite.

Phosphagenics CEO, Dr Esra Ogru, said "the new results further demonstrated the efficacy of the company's platform technology."

"All measurable endpoints continued to improve over the 8 week study duration. It appears that continued use of the BodyShaper Cellulite Contour Crème™ will show increasingly better results in terms of cellulite appearance and skin condition."

"These results should inspire further consumer confidence in Phosphagenics' proprietary platform technology and the entire ELIXIA® range."

Acceptance of the BodyShaper Cellulite Contour Crème™ into department stores represents a strategic step by Phosphagenics toward its goal of establishing this product as a significant part of the multi-billion dollar per annum world market for cellulite reduction products.

Dr Ogru said, "We are thrilled to have our product sitting on shelves next to products of the largest global cosmetics companies. We are justifiably proud of our product and the manner in which we have leveraged our pharmaceutical know-how into a consumer product."

---

### **Phosphagenics Limited**

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: [www.phosphagenics.com](http://www.phosphagenics.com) Email: [info@phosphagenics.com](mailto:info@phosphagenics.com)

BodyShaper Cellulite Contour Crème™ and the complete ELIXIA® range will also be available through TVSN and on-line through [elixia.com.au](http://elixia.com.au).

### **About the Study**

This independent study was conducted by AMA Laboratories Inc in New York. Thirty women participated in the trial which involved morning and night application of the BodyShaper Cellulite Contour Crème™ to the upper thigh of a single leg. The application area was assessed at 2, 4, 6 and 8 weeks for quantifiable changes in the visible appearance of cellulite using advanced digital photographic techniques, as well as measurement of skin hydration, elasticity and thigh circumference. Participants also completed a questionnaire at each time point that recorded their subjective assessments of any perceived improvements. The untreated leg was used as a control for all measurements.

After 4 weeks of application, the appearance of the cellulite at the sites of application was quantifiably reduced by up to 40%. These improvements were visibly noticeable to the participants, with 86% of women reporting a perceived improvement to the visible appearance of the bumps and dimples of their cellulite. They also observed (96%) an improvement to skin firmness and smoothness, while 93% of women saw an increase in skin tightness. Skin hydration was increased by 20% and elasticity increased by 5% over the course of the 4 weeks.

At eight weeks, results demonstrated a reduction of up to 56% in the visible appearance of the cellulite at the application sites. Skin elasticity improved by 25% and hydration levels were 10% better. Ninety percent of women reported a perceived improvement to the visible appearance of the bumps and dimples of their cellulite, with 43% scoring the improvement as "dramatic". The women (96%) also observed an improvement to skin firmness (56% "dramatic") and smoothness, while 93% of women saw an increase in skin tightness (53% "dramatic"). Continued use of the product is expected to further improve the outcomes for all measurable endpoints.

### **Ends**

#### **Enquiries:**

Dr Esra Ogru  
Chief Executive Officer  
Phosphagenics Limited  
+61 3 9565 1119

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

### **About Phosphagenics**

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGY).  
[www.phosphagenics.com](http://www.phosphagenics.com)